A Novel Testosterone 2% Gel for the Treatment of Hypogonadal Males
Authors:
- 8 July 2012
- journal article
- clinical trial
- Published by Wiley in Journal of Andrology
- Vol. 33 (4) , 601-607
Abstract
Testosterone replacement therapy (TRT) can improve the symptoms, signs, and well being of hypogonadal men by restoring serum testosterone concentrations to physiologic levels. This multicenter, open‐label noncomparative trial of men with hypogonadism evaluated the pharmacokinetic profile and safety of a novel testosterone 2% gel (Fortesta™ Gel), administered once daily to the front and inner thighs at starting doses of 40 mg/d. The metered‐dose delivery system allowed dose adjustments in 10‐mg increments between 10 and 70 mg/d. Of the 149 patients enrolled, 138 patients (92.6%) completed the study and 129 patients (86.6%) were included in the efficacy analysis. On day 90, mean testosterone concentration (Cavg [0–24 hours] ± SD) was 438.6 ± 162.5 ng/dL. Overall, 100 (77.5%) patients achieved serum total testosterone concentrations within the normal physiologic range (≥300 and ≤1140 ng/dL). On day 90, mean testosterone Cmax (±SD) was 827.6 ± 356.5 ng/dL. On day 90, a total of 122 patients (94.6%) had Cmax levels of 1500 ng/dL or less and 2 patients (1.6%) had values between 1800 and 2500 ng/dL. Similar results for Cavg (0–24 hours) and Cmax were observed on day 35. All enrolled patients were included in the safety analysis. Testosterone 2% gel was generally well tolerated, with the most common adverse events (AE) being mild and moderate skin reactions. There were no serious AEs related to testosterone 2% gel. Once‐daily testosterone 2% gel restored levels of testosterone in more than 75% of patients, with low risk of supraphysiologic testosterone levels. Patients may find this a suitable option for TRT because of its application site and low volume.Keywords
This publication has 8 references indexed in Scilit:
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in malesInternational Journal Of Impotence Research, 2008
- Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older MenThe Journal of Clinical Endocrinology & Metabolism, 2006
- Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agentsInternational Journal Of Impotence Research, 2005
- AA2500 Testosterone Gel Normalizes Androgen Levels in Aging Males with Improvements in Body Composition and Sexual FunctionThe Journal of Clinical Endocrinology & Metabolism, 2003
- A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual functionBJU International, 2003
- Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal MenThe Journal of Clinical Endocrinology & Metabolism, 2000
- Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center StudyThe Journal of Clinical Endocrinology & Metabolism, 2000